Integrative neuroscience approach to predict ADHD stimulant response

  title={Integrative neuroscience approach to predict ADHD stimulant response},
  author={Daniel F. Hermens and D. L. Rowe and Evian Gordon and Leanne M. Williams},
  journal={Expert Review of Neurotherapeutics},
  pages={753 - 763}
Despite high rates of prescription, little is known about the long-term consequences of stimulant medication therapy for attention-deficit hyperactivity disorder (ADHD) sufferers. Historically, the clinical use of stimulants for ADHD has been based on trial and error before optimal therapy is reached. Concurrently, scientific research on the mechanism of action of stimulants has influenced neurobiological models of ADHD, but has not always informed their prescription. Whilst the two main… 

Drug Therapy of Attention Deficit Hyperactivity Disorder: Current Trends

Current trends in drug therapy of ADHD are discussed, the promise pharmacogenomics may hold in the future is highlighted, and the use of nonstimulant drugs like atomoxetine and various other drugs, such as a-agonists, and a few antidepressants, being used in an off-label manner are highlighted.

tomoxetine Improved Response Inhibition in Adults ith Attention Deficit/Hyperactivity Disorder

The selective noradrenaline reuptake inhibitor atomxetine shows efficacy in the treatment of ADHD and epresents the only licensed nonstimulant pharmacologic treatent currently available for the disorder.

Neuroimaging markers for the prediction of treatment response to Methylphenidate in ADHD.

Neuroimaging-Aided Prediction of the Effect of Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder: A Randomized Controlled Trial

Although methylphenidate hydrochloride (MPH) is a first-line treatment for children with attention-deficit hyperactivity disorder (ADHD), the non-response rate is 30%. Our aim was to develop a

Effects of methylphenidate on the ERP amplitude in youth with ADHD: A double-blind placebo-controlled cross-over EEG study

It is suggested that mental fatigue plays a role in the decrease of the P3 response in the placebo condition compared to pre-placebo, a phenomenon that is significant in ADHD subjects but not in controls, and which is interestingly rectified by MPH.

Off-label prescription of quetiapine in psychiatric disorders

  • D. Rowe
  • Psychology, Medicine
    Expert review of neurotherapeutics
  • 2007
It is suggested that low-dose quetiapine shows good tolerability and efficacy in patients diagnosed with these disorders, particularly in the case of treatment-resistant patients that do not respond to primary treatments including SSRIs and cognitive–behavioral therapy.

Treatment-resistant attention-deficit hyperactivity disorder: Clinical significance, concept, and management

It is suggested that the more ideal strategy of defining treatment resistance should consider the improvement of ADHD symptoms and the global functioning simultaneously, and the optimal medication adjustment or the combination of medications and psychotherapy may be the potential therapeutic strategy for treatment-resistant ADHD.

Effects of Methylphenidate and Atomoxetine on Development of the Brain

This chapter provides general information about the brain development process and the effects of MPH and ATX on neurodevelopment in the light of the actual findings and the literature.

A Position Paper on Neurofeedback for the Treatment of ADHD

The purpose is to demonstrate the rationale and to reference the necessary support for neurofeedback in order to be recognized as a legitimate, scientific, and evidence-based intervention for the treatment of ADHD.



Non-Stimulant Treatment of Attention-Deficit/Hyperactivity Disorder

Clinical guidelines for each of these agents, as well as their use in combination with stimulants in comorbid conditions, will be discussed.

Predicting stimulant medication response in ADHD: evidence from an integrated profile of neuropsychological, psychophysiological and clinical factors.

The value of integrating neuropsychological and psychophysiological data in predicting medication response in ADHD is indicated, as better response was associated with increased resting beta power and decreased WM distractor P3.

Stimulant Effects in Attention Deficit Hyperactivity Disorder: Theoretical and Empirical Issues

  • C. Denney
  • Psychology
    Journal of clinical child psychology
  • 2001
This discussion suggests that theory-based experimental manipulations of task and setting variables designed to impose challenge on hypothesized core features of the disorder are more likely to yield insights into the causal mechanisms governing behavioral organization in affected children than strategies emphasizing static identification of diagnostic correlates.

Stimulant treatment for children: a community perspective.

In this area of the Great Smoky Mountains, stimulant treatment was being used in ways substantially inconsistent with current diagnostic guidelines.

Attention-deficit/hyperactivity disorder: a life-span perspective.

  • J. Biederman
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 1998
A variety of pharmacologic agents are available in treating ADHD: stimulant medications remain the first-line treatment for noncomorbid ADHD, whereas tricyclic antidepressants and bupropion are recommended for stimulant nonresponders and patients with more than one psychiatric disorder.

Prediction of stimulant response in children with attention-deficit/hyperactivity disorder.

Discrimination of stimulant-responding and nonresponding groups of children with attention-deficit/hyperactivity disorder (ADHD) on the basis of demographic, neurophysiologic, or behavioral variables